GlassScriptPhysician profile
Robert W Kahan
NPI 1790871671
$7,378.35
in general payments reported to CMS, 2019-2025
29 companies · $672 in 2025
The $672 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,231 · 2020: $825 · 2021: $723 · 2022: $1,692 · 2023: $1,214 · 2024: $1,020 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,898 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,897.58 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,280.24 | 2019-2024 | Aveir, Jot Dx, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $714.55 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $710.71 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $695.81 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $675.11 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $554.85 | 2019-2025 | |
| Pfizer INC. | $536.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $491.48 | 2019-2024 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.49 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $218.88 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $156.52 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $131.93 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $107.41 | 2019-2022 | |
| Heartflow, INC. | $100.81 | 2022-2023 | Ffrct |
| Lilly USA, LLC | $99.37 | 2023-2025 | Mounjaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $90.05 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $89.97 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $55.90 | 2023-2024 | Inpefa |
| Boston Scientific Corporation | $43.66 | 2022-2023 | Watchman Access System |
| Preventice Services, LLC | $40.02 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $37.24 | 2024 | Arcalyst |
| Philips North America LLC | $27.13 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Alnylam Pharmaceuticals INC. | $23.83 | 2022 | |
| Vifor Pharma, INC. | $23.76 | 2020 | |
| Lundbeck LLC | $22.49 | 2019 | |
| Bardy Diagnostics, INC. | $17.71 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.60 | 2025 | |
| Astellas Pharma US INC | $13.65 | 2019 | |
| Biobeat USA INC. | $13.03 | 2024 | Bb-613 Bpm Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.